Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [615]

ASCO 2012: Metastatic castration-resistant prostate cancer; abiraterone acetate...

Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Karim Fizazi from...

ASCO 2012: Metastatic castration-resistant prostate cancer; abiraterone acetate COU-AA-302 study ( Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Karim Fizazi from Institut Gustave Roussy, France )

ASCO 2012: Advances in pre-operative care in high-risk mCRCP

Dr Chris Parker - Royal Marsden Cancer Centre, UK; Prof Eleni Efstathiou - MD...

ASCO 2012: Advances in pre-operative care in high-risk mCRCP ( Dr Chris Parker - Royal Marsden Cancer Centre, UK; Prof Eleni Efstathiou - MD Anderson Cancer Centre, USA )

ASCO 2012: Advances in metastatic castration-resistant prostate cancer with...

Dr Karim Fizazi - Institut Gustave Roussy, France; Dr Oscar Goodman - Nevada...

ASCO 2012: Advances in metastatic castration-resistant prostate cancer with abiraterone ( Dr Karim Fizazi - Institut Gustave Roussy, France; Dr Oscar Goodman - Nevada Cancer Institute, USA )

Intermittent hormonal therapy versus continuous therapy for advanced prostate...

Dr Maha Hussain - University of Michigan, Ann Arbor, USA

Intermittent hormonal therapy versus continuous therapy for advanced prostate cancer ( Dr Maha Hussain - University of Michigan, Ann Arbor, USA )

Intermittent hormonal therapy less effective than continuous therapy when...

Dr Maha Hussain - University of Michigan, Ann Arbor, USA

Intermittent hormonal therapy less effective than continuous therapy when treating advanced prostate cancer ( Dr Maha Hussain - University of Michigan, Ann Arbor, USA )

Highlights and goals of IMPAKT 2012

Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium

Highlights and goals of IMPAKT 2012 ( Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium )

Endocrine therapy and endocrine resistant breast cancer

Prof Mitch Dowsett – The Institute for Cancer Research, London, UK

Endocrine therapy and endocrine resistant breast cancer ( Prof Mitch Dowsett – The Institute for Cancer Research, London, UK )

Targeting DNA damage response and repair excluding PARP for triple negative...

Prof Thomas Helleday - Karolinska Institutet, Stockholm, Sweden

Targeting DNA damage response and repair excluding PARP for triple negative breast cancer ( Prof Thomas Helleday - Karolinska Institutet, Stockholm, Sweden )

Molecular characterisation of breast cancer: the mutational landscape

Prof Sam Aparicio - University of British Columbia, Vancouver, Canada

Molecular characterisation of breast cancer: the mutational landscape ( Prof Sam Aparicio - University of British Columbia, Vancouver, Canada )

New cyclin-dependent kinase inhibitor with letrozole for ER+/HER2- breast cancer

Prof Richard Finn - Universtity of California, Los Angeles, USA

New cyclin-dependent kinase inhibitor with letrozole for ER+/HER2- breast cancer ( Prof Richard Finn - Universtity of California, Los Angeles, USA )

Criteria required before implementation of whole genome arrays in clinical...

Prof Daniel Hays - University of Michigan, Ann Arbor, USA

Criteria required before implementation of whole genome arrays in clinical practice ( Prof Daniel Hays - University of Michigan, Ann Arbor, USA )

Prognostic significance of progesterone receptor-positive tumour cells within...

Dr Aleix Prat - University of North Carolina, USA

Prognostic significance of progesterone receptor-positive tumour cells within luminal A breast cancer ( Dr Aleix Prat - University of North Carolina, USA )

More from ecancer